Source and scope
This summary is bounded to the recommendations, population and decisions covered by Living Guideline for the Management of Axial Spondyloarthritis: April 2026 update. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CRA/SPARCC axSpA 2026
Source-attributed clinical priorities
- Recognize inflammatory back pain, enthesitis, dactylitis, uveitis, psoriasis and inflammatory bowel disease associations.
- Do not exclude axial spondyloarthritis solely because inflammatory markers, HLA-B27 or plain radiographs are normal.
- Refer suspected inflammatory disease for rheumatology assessment and maintain exercise and cardiovascular-risk care.
- Ask about uveitis, psoriasis, inflammatory bowel disease and family history because extra-articular clues support recognition.
sources for this section:CRA/SPARCC axSpA 2026
Practical assessment and management workflow
1
Characterize morning stiffness, night pain, exercise response, enthesitis, dactylitis and peripheral synovitis.
2
Examine spine mobility, sacroiliac provocation, entheses, joints, skin, nails and eyes.
3
Order inflammatory markers and appropriate pelvic imaging without using normal results to exclude early disease.
4
Refer suspected axial or peripheral inflammatory disease and track activity, function and treatment toxicity.
sources for this section:CRA/SPARCC axSpA 2026
Safety, red flags and urgent escalation
- A painful red photophobic eye requires urgent ophthalmic assessment for uveitis.
- Escalate acute neurologic compromise or possible spinal fracture, especially in an ankylosed spine.
- Screen infection and update vaccination before biologic or targeted immunomodulatory therapy.
sources for this section:CRA/SPARCC axSpA 2026
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CRA/SPARCC axSpA 2026
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CRA/SPARCC axSpA 2026
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Canadian Rheumatology Association and Spondyloarthritis Research Consortium of CanadaLiving Guideline for the Management of Axial Spondyloarthritis: April 2026 updateLiving guideline update 1; April 2026 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.